For Research Use Only

Recombinant Human FGFR2(IIIb) protein (hFc Tag, Myc Tag, His Tag)

www.ptgcn.com

Catalog Number: Eg0175

Basic Information

Species:
Human

Purity:
>90 %, SDS-PAGE

Tag:
hFc Tag, Myc Tag, His Tag

Technical Specifications

Purity:
>90 %, SDS-PAGE

Endotoxin Level:
<1.0 EU/ μ g protein, LAL method

Source:
HEK293-derived Human FGFR2(IIIb) protein Arg22-Glu378 (Accession# P21802-3) with a human IgG1 Fc tag, a Myc tag and a His tag at the C-terminus.

GeneID:
2263

Accession:
P21802-3

Predicted Molecular Mass:
71.1 kDa

SDS-PAGE:

Formulation:
Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Not tested

Storage and Shipping

Storage:
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20℃ to -80℃ as lyophilized proteins.
- 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.

Shipping:
The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

FGFR2 (Fibroblast growth factor receptor 2) is a tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration, and apoptosis. Ligand binding leads to the activation of several signaling pathways, such as RAS, MAPK1/ERK2, MAPK3/ERK1, and the MAP Kinase signaling pathway, as well as the AKT1 signaling pathway. Mutations in the gene of FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. This polyclonal antibody raised against 358-704aa of human FGFR2 can cross-react with other members of the FGFR family.

References

1. Vogel, Arndt et al. Annual review of medicine vol. 74 (2023): 293-306.
2. Goyal, Lipika et al. The New England journal of medicine vol. 388,3 (2023): 228-239.
3. Subbiah, Vivek et al. Cancer discovery vol. 13,9 (2023): 2012-2031.
4. Zingg, Daniel et al. Nature vol. 608,7923 (2022): 609-617.

Synonyms

FGFR2, BEK, BFR 1, CD332, CEK3

Selected Validation Data